Journal of Antimicrobial Chemotherapy (1995) 36, 165-172
© 1995 The British Society for Antimicrobial Chemotherapy
research-article |
The pharmacokinetics of meropenem in surgical patients with moderate or severe infections
Regional Antibiotic Reference Laboratory, Southmead Health Services NHS Trust Westbury-on-Trym, Bristol BS10 5NB, UK aDepartment of Medical Microbiology, Southmead Health Services NHS Trust Westbury-on-Trym, Bristol BS10 5NB, UK bDepartment of Surgery, Southmead Health Services NHS Trust Westbury-on-Trym, Bristol BS10 5NB, UK
Received 20 September 1994; accepted 4 January 1995
The pharmacokinetics of meropenem were studied in a group of 11 surgical patients (four male, seven female; mean age 63years; mean weight 72 kg) all of whom had moderate or severe infection and who received a mean dose of 14.5 mg/kg ± 2.7 meropenem 8-hourly iv for a minimum of 4 days. Venous blood samples were collected at timed intervals after the first dose on day 1 and the second dose on the fourth or fifth day of therapy. Serum meropenem concentrations were assayed by HPLC and fitted to a two compartment pharmacokinetic model. The mean pharmacokinetic parameters (± standard deviation) on day 1 were T
12 84.6 ± 24.1 min, Vdst 0.22 ± 006 L/kg, AUC 6028 ± 1983–2mg.min/L, Cltot 188 ± 67mL/min and MRT 89.1 ± 67.8 min. On the fourth or fifth days of therapy the values were T12 79.9 ± 18.2 min, Vdst. 0.17 ± 0.8 L/kg, AUC 6000.7 ± 2417 mg.min/L, Cltot 190 ±60 mL/min and MRT 67.8 ± 30.4 min. Although the T12, Vdts and MRT decreased from day 1 to day 4 or 5 these changes were not statistically significant (Student's t-test, P > 0.05). Total clearance of meropenem was linearly related to creatinine clearance or patient age on the first day of therapy. Although the T12 and MRT were longer and the Cltot lower than those reported for young healthy volunteers, they were similar to those found in elderly volunteers. As the pharmacokinetic parameters remained constant over the duration of therapy rather than being related to severity of infection or surgery we conclude that dosage modification of meropenem is not required for patients with moderate or severe infection.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Isla, J. Maynar, J. A. Sanchez-Izquierdo, A. R. Gascon, A. Arzuaga, E. Corral, and J. L. Pedraz Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients J. Clin. Pharmacol., November 1, 2005; 45(11): 1294 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Krueger, J. Bulitta, M. Kinzig-Schippers, C. Landersdorfer, U. Holzgrabe, K. G. Naber, G. L. Drusano, and F. Sorgel Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1881 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Harding, A. P. MacGowan, L. O. White, E. S. R. Darley, and V. Reed Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome J. Antimicrob. Chemother., June 1, 2000; 45(6): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. R. Darley, K. E. Bowker, A. M. Lovering, J. E. Harvey, and A. P. Macgowan Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis J. Antimicrob. Chemother., February 1, 2000; 45(2): 247 - 250. [Abstract] [Full Text] [PDF]
|
|